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Specific Aims:
1. Application of the bioreactor to enhance cytokine-regulated proliferation and maturation of dendritic
cells (DC).
2. Based on clues from spaceflight: compare the frequency and function of DC in normal donors and
immunocompromised cancer patients.
3. Initiate studies on the efficiency of cytokine therapy and DC-assisted immunotherapy (using
bioreactor-expanded DC) in animal models of experimental fungal infections.
Studies and Results:
Several novel and important observations were made during Round 1 which provide new insight
into DC immunobiology, DC dysfunction in cancer patients, and characteristics of DC growth in the 3-
dimensional culture conditions of the NASA bioreactor. These studies are summarized below.
Additional details are provided in the attached manuscripts (Appendices 1 and 2).
Generation of DC from CD34 + progenitor cells in NASA bioreactors. We and others have shown that
human DC can be generated from early hematopoietic progenitors (i.e. CD34 ÷ cells isolated from bone
marrow or from G-CSF mobilized
peripheral blood) cultured for 1-3
weeks with cytokines in standard 2-
dimensional tissue culture conditions.
We now report that DC generation
and maturation can also be achieved
within the 3D environment of the
NASA bioreactors (including the
HARV, STLV and RCCS-D vessels).
These DC were identified primarily by
their characteristic morphology
(numerous elongated cytoplasmic
processes; Fig. 1), but also by their
Fig 1. Morphology of DC generated from CD34 progenitors in the NASA bioreactor.
Note the thinly veiled cell with long, branched processes in the center of the left panel
and the elongated cell spanning the right panel.
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lack of lineage (lin) -associated surface markers, high expression of
HLA-DR Class II molecules, and high allostimulatory activity in a _
mixed lymphocyte reaction - the latter function is considered a _
hallmark of DC (Fig. 2).
However, several intriguing differences were observed when _
the DC generated in the bioreactors were compared to those generated _
Fig. 2 Superior allostimulatory activity of DC generated in the NASA bioreactor. DC
generated in standard 2D and 3D bioreactor (bio) cultures were tested for the ability to
stimulate an allogeneic mixed lymphocyte reaction (1:40 DC:lymphocyte ratio). Both DC
populations were substantially more efficient stimulators compared to unseparated
mononuclear cells (MNC), even when the latter were tested at a ratio as high as 1:1.
Unstim = responder cells cultured without stimulators.
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Fig. 3 Proliferative and phagocytic activity of DC
generated in 2D cultures and 3D bioreactors (Bio). Left
panel: expansion index = no. cells after 10 days of
culture + no. cells at start of culture. Right panel:
percentage of DC ingesting Aspergillus conidia.
Representative experiments are shown.
in 2D: first, while cells proliferated in both conditions, the
overall cell expansion in the 3D bioreactors within a 10-21
day period was only 25-50% of that achieved in 2D (Fig. 3,
left panel); second, DC generated in the bioreactor displayed a
reduced ability to phagocytose Aspergillus conidia (Fig. 3,
right panel); third, despite these deficiencies in antigen uptake
and proliferation, DC generated in 3D bioreactors often
displayed higher allostimulatory activity (Fig. 2); fourth, cells
from 3D cultures displayed higher levels of heat shock
proteins (Hsp) (Fig. 4). While Hsp are upregulated by various
stressors, as molecular chaperones they are involved in many
processes in unstressed cells, including proliferation, antigen
presentation, etc. Upregulation of Hsp in DC may reflect
alterations in cellular functions.
According to current models, DC maturation progresses from a less mature stage characterized by
high antigen uptake/processing capabilities and low antigen-presenting function, to a more mature stage in
which antigen uptake/processing capabilities are lost as antigen-
presenting functions are enhanced. If this model is correct, our data _ _
would suggest that the DC generated in the bioreactors may be more _ _ c_
mature than those from 2D cultures. As discussed below, this
observation is important in light of the general opinion that terminally HspZ7
differentiated DC will be more suitable for therapeutic purposes.
Fig. 4 Upregulation of heat shock
proteins in DC generated in the NASA
bioreactor (Bio). Hsp27 was detected in
lysates of DC and HeLa cells (positive
control) using standard Westem blotting
techniques.
Comparison of DC of normal donors and immunocompromised cancer
patients (Appendices 1 and 2). Patients recovering from stem cell
transplantation are immunocompromised and thus at high risk of
infection. We hypothesized that a deficiency in DC might be an
underlying cause of the lymphopenia experienced by these patients, since antigen presenting cells are
required for the optimum activation and proliferation of T lymphocytes. Because DC are present in only
trace amounts in blood, it is not possible to purify these cells from severely lymphopenic individuals.
Therefore, we devised a method to detect DC directly within peripheral blood mononuclear cell (PBMC)
samples - a technique that required only small samples of blood and minimal manipulation (i.e. Ficoll-
hypaque separation).
First, we used multidimensional flow cytometry to show that magnetically sorted DC isolated from
blood of normal donors displayed a morphology, size profile, surface phenotype and functional properties
of typical DC described previously by other investigators, i.e. these DC displayed high forward light
scatter (Appendix 1); expressed CD4, HLA-DR (MHC-Class II), CD86 (costimulatory molecules), and
CD54 (adhesion/costimulatory molecules) surface structures, but lacked the lin markers of T cells, NK
cells, B cells, macrophages or granulocytes (Fig. 5 and Table 1). These lin'DR ÷ cells also displayed high
allostimulatory activity (Fig. 6), and showed the typical morphology of DC after culture with GM-CSF
and TNFc_ (Fig. 7). Next, we used a cocktail of antibodies directed against the lin antigens (first color)
and anti-HLA-DR (second color), to establish that lin-DR + DC-like cells could be detected directly in
unseparated PBMC samples (Fig. 8). When analyzed by 3-color flow cytometry, these lin-DR ÷ DC, like
the sorted DC, coexpressed CD4, CD86 and CD54 surface antigens (Table 1). Using this technique, we
then analyzed PBMC from breast cancer patients (all undergoing some form of chemotherapy) and
patients who were 2-6 months post stem cell transplantation. Fig. 9 indicates that the number of
circulating DC detected in both groups of patients was significantly lower than that of normal donors.
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Fig. 5 Enrichment of lineage negative HLA-DR ÷ (lin'DR ÷) leukocytes
by immunomagnetic sorting. Unsorted PBMC (Panels A) and cells
sorted using a DC isolation kit (Panels B) were analyzed by flow
cytometry. DC-like cells were characterized as the iin'DR ÷ events in
quadrant 4. The lineage cocktail consisted of PE-conjugated mAbs
recognizing TCRct[3, TCRyS, CD19,CD56 and CDI4 antigens.
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Fig. 6 Allostimulatory activity of immuno-
magnetically sorted linDR * cells.
Table 1. 3-Color flow cytometric analysis of lin-DR* leukocytes in
unsorted and immunoma_netically sorted peripheral blood specimens.
Expt. Percent of lin-DR+ cells coexpressing the particular
antigen
No. CD4 CD54 CD86 CD80 CD ! a
Fig. 7. Morphology of immuno-
magnetically sorted linDR ÷ leukocytes.
PBMC-I 94.6 98.1 93.2 5.3 6.0
2 87.2 93.6 86.5 0.6 0.3
3 92.2 97.4 99.3 1.6 1.3
Sorted ! 92.2 99.3 1.6 2.0
2 99.3 87.5 4.5
3 98.8 86.5 3.2 6.7
Lin-DR+ cells in unsorted PBMC or immunomagnetically sorted
populations were analyzed for coexpression of several other surface
markers using 3-color flow cytometric analysis. Sorted cells were
positively selected for CD4 expression and not reanalyzed for this
antigen..
1°4 ! A I . , ..
]_ :
10 0 1_2 ' "_k_@_l e " " --"" "m
H LA-I_R (FITC)
_'°'i 'N
,oO F':'-_oV"'_oi'"",o_....4 1,
HI.A-DR (TRI)
04
Fig 8 Flow cytometric analysis of lin'DR ÷ leukocytes
within PBMC preparations. Panel A: PBMC were
labeled with a cocktail of PE-conjugated mAbs
recognizing CD3, CDI9, CD20, CDI6, CD56, CDllb
and CDI4, and FITC-conjugated anti-HLA-DR mAbs.
Panel B: The same population was labeled with a
cocktail of FITC-conjugated lineage mAbs and TRI-anti-
HLA-DR. The boxed lin'DR* events in quadrant 4 were
further analyzed for coexpression of a third marker
(results shown in Table !).
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Fig. 9 Frequency of lin'DR ÷ cells in PBMC of
normal donors and cancer patients. Patients
included 7 breast cancer patients who received
prior chemotherapy (chemo) and 5 patients
who had received stem cell transplants
(chemo+SC) 2-6 months prior to testing.
Horizontal lines represent the mean.
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A similar analysis was performed on peripheral blood and ascites fluid samples of ovarian cancer
patients (see manuscript, Appendix 2). In these patients also, the frequency of circulating DC-like linDR ÷
cells in blood was reduced compared to normal donors (0.4 + 0.3% versus 0.9 + 0.3%, respectively;
p<0.02) Interestingly though, a higher proportion of linDR ÷ cells was detected within the ascites fluid
compared to blood samples from the same patients (4.5 + 5.7% versus 0.5 + 0.4%, respectively; p<0.05).
However, the ascites-derived DC expressed a the lower density of HLA-DR molecules compared to DC in
peripheral blood, suggesting that they might have been negatively affected by factors associated with the
tumor environment. All of these studies point to the potential usefulness of multidimensional flow
cytometry for evaluation of DC in various tissue compartments.
Analysis of murine DC generated in the NASA bioreactor. Our studies of murine DC are still underway,
but indicate that these cells can also be cultivated from unseparated bone marrow cell suspensions in the
RCCS-D. In fact, a higher proportion of NLDC-145 + cells (a
surface marker expressed by murine DC) has been detected
in 3D bioreactor cultures compared to standard 2D
conditions (Table 2). Somewhat in contrast to the human
studies, we have observed a higher proliferation of murine
cells within the bioreactor compared to standard 2D cultures.
Future studies will compare the ability of 2D and bioreactor-
generated DC to protect mice from infection with
Aspergillus or Candida.
Table 2. Generation ofmurine DC in the
NASA bioreactor
Expt. % NLDC-145 ÷ cells
No. 2D Cultures 3D Bioreactor
l 3 18
2 9 24
Significance. DC are considered to be the most potent of antigen presenting cells. Only recently though,
has it been possible to expand this rare leukocyte subset in vitro in cytokine-supplemented cultures. To
our knowledge, our studies are the first of their kind to generate and cultivate DC in a 3D environment.
One of our long-term goals is to generate sufficient numbers of fully differentiated DC for in vivo
supplementation/restoration of patients who we now show have low numbers of circulating DC. These
DC could be pulsed in vitro with antigen and then infused to stimulate naive or resting T lymphocytes
(DC-assisted vaccination). Alternatively, T cells could be collected, exposed to antigen-pulsed DC in
vitro, and then reinfused.
Despite several advances in the field of DC and the intense interest that has been focused on
cultivating these cells, there are several issues that still must be addressed before DC gain widespread
clinical application. One particular obstacle has been the inability to define the conditions/stimuli that
promote the terminal, irreversible, differentiation of DC. Unless this stage of maturation is achieved, DC
might lose their function or revert to a less differentiated state after in vivo instillation. This could not
only diminish the effectiveness of treatment, but could also induce T cell anergy if critical costimulatory
molecules are downregulated. Our observations, that DC generated in the bioreactor may be more
differentiated than those obtained in standard 2D cultures is therefore important, because if stable
differentiation can be achieved, this may represent a novel approach for generating DC for therapeutic
purposes.
While early emphasis was placed on defining conditions for generating massive numbers of DC, it
is becoming increasing evident that it is the quality rather than the quantity of DC which will ultimately
determine their therapeutic effectiveness. Therefore, the decreased cell expansion observed in bioreactor-
grown DC is not likely to be problematic. Importantly, this system will provide us with the opportunity to
analyze in depth the cellular and molecular events associated with DC maturation from its earliest
progenitor to terminal differentiation, as this entire process appears to be accomplished in the bioreactor.
This information will be important to understanding the mechanism of DC dysregulation in cancer
patients, and may be applicable also to understanding changes in DC that might contribute to the blunting
of immunity associated with spaceflight.
4
Principal Investigator: Cherylyn A. Savary, Ph.D.
Our findings that circulating DC are significantly reduced in patients with gynecologic cancers,
and in individuals recovering from stem cell transplantation are novel. Future studies are planned to
determine whether this effect is related to the disease-state or to the chemotherapy. The functional
capabilities of the small numbers of DC-like cells detected in these patients remains to be determined, but
the lower levels of DC might contribute to the inability of patients to mount an effective anticancer
response and could explain the increased susceptibility of these patients to opportunistic infections. As
discussed above, bioreactor-grown DC might eventually be used to correct these deficiencies.
Furthermore, our observations suggest that the multidimensional flow cytometric technique described here
could be used to monitor DC recovery after transplantation and to evaluate the effect of various treatment
regimens or environmental conditions on DC frequency or maturation. Such a tool might also aid in
identifying therapies that spare or boost immunity. In fact, DC testing might become routine in any
comprehensive immunological evaluation of patients and space travelers.
Our finding of increased Hsp in cells cultured in the bioreactor is intriguing. Upregulation of these
stress proteins might reflect a protective response of DC against as yet undefined stressors, some of which
might resemble those experienced in microgravity. Since Hsp have been shown to be involved in antigen
presentation, changes in Hsp expression could also cause the altered function of DC cultured in the
bioreactor. Understanding the role of Hsp in DC maturation might provide new insight into the molecular
pathways that may be disturbed in disease or in space. We have received funding to explore this new
avenue of research, that represents a spin-off of the present studies, through NRA-96-OLMSA-03.
Future Studies: Many of the above described studies are continuing in Round 2. We are presently
evaluating DC in patients undergoing cytokine therapy to determine if DC number and function are
altered, and how this might relate to the clinical response. We are also conducting an in depth analysis of
the maturational status of DC grown in the bioreactor as reflected by changes in particular cell surface
markers known to be differentially expressed by less mature versus more mature DC, and by functional
tests. We will also study the in vivo effectiveness of DC generated in the bioreactor to protect against
fungal infections in a murine model.
Manuscripts submitted:
Savary CA, Grazziutti ML, Melichar B, Przepiorka D, Freedman RS, Cowart RE, Cohen DM, Anaissie EJ, Woodside DG,
Mclntyre BW, Pierson DL, Pellis NIL Rex JH. Multidimensional flow cytometric analysis of dendritic cells in peripheral blood
of normal donors and cancer patients. Cancer Immunol. lmmunother. (submitted).
Melichar B, Savary CA, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, Freedman RS. Lineage
negative HLA-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and
pelvis. Cellular Immunol. (submitted).
Funding resulting from these studies:
NRA-96-OLMSA-03 "Use of NASA Bioreactors in a Novel Scheme for Immunization Against Cancer"
PI: C.A. Savary, Ph.D.; FY 1997 to FY 2000; $465,000
Other activities/accomplishments during Round 1:
Feb. 1997 - presented results of the present studies at the annual meeting of the Biotechnology Cell Science Program
Investigators Working Group.
Student involvement in these studies -
Monica Grazziutti, M.D., Clinical Fellow
Luis Tome, M.D., Clinical Fellow
Alysson Ford, summer student, King Foundation Summer Research Program
Lee Aleksich, summer student, NASA Sharp Plus/Qem Program
Manu Goyal, summer student; NASA Sharp Plus/Qem Program
abstract of project accepted for presentation at the AJAS/AAAS conference (Appendix 3)
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Abstract We studied the potential of multidimensional flow cytometry in evaluation of the
frequency and maturation/activation status of dendritic cells (DC) in minimally manipulated
peripheral blood mononuclear cell preparations (i.e., Ficoll-Hypaque separated only) of normal
donors and cancer patients. A rare subset of HLA-DR + leukocytes (<1% of mononuclear cells)
was detected in blood of normal donors that displayed all the features of DC: these cells had high
forward light scatter characteristics and coexpressed CD4, CD86 and CD54 surface antigens, but
lacked the lineage-associated surface markers of T cells, B cells, monocytes, granulocytes or NK
cells (i.e. they were CD3", CD19", CD20", CD14", CD1 lb', CD16", CD56"). These physical and
phenotypic properties were virtually identical to those of immunomagnetically sorted leukocytes
characterized as DC on the basis of morphology, phenotype and high stimulatory activity in
allogeneic mixed lymphocyte cultures. Using this flow cytometric approach we observed that the
frequency of DC-like cells in peripheral blood mononuclear cell specimens of cancer patients
receiving chemotherapy alone or those recovering from stem cell transplantation was significantly
lower than that of normal individuals (mean + SE: 0.36 + 0.05%, 0.14 + 0.06%, and 0.75 +
0.04%, respectively). Multidimensional flow cytometric analysis of DC might represent an
important new tool for assessing immunocompetency, and for monitoring the effects of
therapeutic regimens on the immune system.
Key words Dendritic cells • Flow cytometry • Stem cell transplantation • Breast cancer
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Introduction
Dendritic cells (DCs) are a subset of bone marrow-derived leukocytes present in trace
amounts in virtually all tissues with the exception perhaps of brain [7]. Because they express
MHC Class I and Class II molecules and the costimulatory structures required for optimal
activation of naive and memory T lymphocytes, DCs have been considered to be the most efficient
of antigen-presenting cells (APC) [7]. The study of DCs has been difficult, though, because of
their very low numbers in peripheral blood and other tissues. Another difficulty has been the
failure thus far to identify any unique surface marker that could be used to directly enumerate,
isolate, and analyze human DCs. Furthermore, evidence suggests that the phenotype of DCs may
vary depending on the stage of maturation or activation, and tissue source. As a result, DCs are
usually identified (a) morphologically, by their numerous cytoplasmic processes [7], (b)
phenotypically, by their expression of HLA-DR and B7 costimulatory molecules, and lack of
surface markers associated with mature NK cells, B cells, T cells, macrophages/monocytes, or
granulocytes [2, 6], and (c) functionally, by their potent T cell-stimulatory activity [2, 7].
Much of our information on human peripheral blood DCs has come from analysis of DCs
that are highly-enriched through rigorous and multiple fractionation procedures [2, 7, 11]. Since
DC are estimated to represent <1% of mononuclear cells, such studies require a large amount of
peripheral blood. Thus investigations using enriched DC are impractical for many studies
involving patients, particularly those with leukopenia. Furthermore, the cell loss that occurs from
the multiple manipulations involved in DC enrichment may decrease the accuracy of the results.
Finally, DC isolation is too complex and time-consuming for routine analysis of patient samples.
Therefore, we investigated the feasibility of using multidimensional flow cytometry to analyze DC
directly in peripheral blood mononuclear cell (PBMC) samples obtained with only minimal
manipulation, i.e. Ficoll-Hypaque gradient separation. We show that the phenotype and light-
scatter properties of these cells are indistiguishable from DC isolated by immunomagnetic sorting.
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Finally,we showthe usefulnessof this techniquein evaluatingthe DC-like subsetin peripheral
bloodspecimensfrom cancerpatients.
Materials and methods
Preparation ofmononuclear cells
Peripheral blood from normal donors and cancer patients was obtained by venipuncture
and collected into heparinized vacutainer tubes. Patients included 7 with breast cancer who were
undergoing standard chemotherapy treatments and 6 individuals recovering from autologous or
allogeneic stem cell transplantation (1 with acute myelogenous leukemia, 1 with lymphoma, and 4
with breast cancer). In some studies buffy coat samples from normal donors were purchased from
a local blood bank. Blood specimens were diluted with 2 parts Ca++/Mg++-free phosphate
buffered saline (PBS), layered onto Accu-Prep gradient solution (density = 1.077 g/ml; Accurate
Chemical and Scientific Corp., Westbury, NY), and centrifuged at 750 x g for 20 min. The
PBMC were collected from the interface and washed 3 times in PBS.
Flow cytometry
Cell surface phenotype was examined by 2- and 3-color immunofluorescence using
monoclonal antibodies (mAbs) that were directly conjugated to fluorescein isothiocyanate (FITC),
R-phycoerythrin 0aE), or Tri-color ® (TRI). The specificity and source of these mAbs are listed in
Table 1. For 2-color flow cytometric detection of DC in PBMC preparations, 106 cells were
incubated for 20 min at 4°C with FITC-conjugated anti-HLA-DR, together with a cocktail of PE-
conjugated mAbs reactive against CD3, CD1 lb, CD14, CD16, CD19, CD20, and CD56. The
latter lineage (lin) cocktail was titrated to label simultaneously all NK cells, T cells, B cells,
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monocyte/macrophages, and granulocytes. Cells labeled with PE- and FITC- conjugated isotype
control mAbs that were nonreactive to human cells were used as a control. The labeled cells were
washed, fixed with 1% paraformaldehyde, and analyzed using a FACScan flow cytometer (Becton
Dickinson Immunocytometry Systems, San Jose, CA) equipped with a single 488 nm argon laser
and 3 fluorescence detectors with filter settings for FITC (530 nm), PE (585 nm) and TRI/PerCP
(>650 nm). A total of 30,000 to 50,000 events were collected in list mode and analyzed using
FACScan Research Software (Becton Dickinson). FSC and SSC gates were set to exclude
erythrocytes and debris, and markers set to exclude background fluorescence as established using
appropriate isotype controls. In these experiments DC were identified as lin'DR ÷ leukocytes with
high forward light scatter (FCS) properties.
For 3 color flow cytometric analysis of DC, 106 cells were labeled simultaneously with a
FITC-Iin cocktail, TRI-conjugated anti-HLA-D1L and a PE-conjugated mAb recognizing one of
the following cell surface determinants: CDla, CD4, CD54, CD80, or CD86. The cells were
washed and fixed with 1% paraformaldehyde. For flow cytometric analysis, a live gate was set on
the lin'DR ÷ DC population (i.e. FITC,TRI÷), and 1000-2000 gated events routinely collected.
This population was then analyzed for co-expression of a third marker identified as positive events
(above background fluorescence) within the PE-channel.
Immunomagnetic sorting of DCs
Highly-enriched preparations of DCs were obtained by immunomagnetic separation using
DC isolation kits obtained from Miltenyi Biotec, Inc., Auburn CA [4]. The isolation procedure
included a negative selection step to remove NK cells, T cells, and monocytes, followed by
positive selection of CD4 ÷ DCs. Briefly, PBMC were suspended in cold PBS supplemented with
2 mM EDTA and 0.5% bovine serum albumin (Fraction V, Sigma Chemical Co., St. Louis, MO)
at a concentration of 3 x 108 cells/ml. The cells were incubated for 10 min at 4°C with an FcR
blocking reagent and a cocktail of mAbs recognizing CD3, CD1 lb and CD16 antigens. The
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suspensionwas thenwashed,andincubatedfor an additional15min at 4°C with paramagnetic
microbeadsrecognizingthe mAb cocktail. This suspensionwaspassedthrougha type CS iron
fiber depletioncolumn placedwithin a strong magneticfield (SuperMACS,Miltenyi Biotec).
Effluent cells that were depletedof macrophages,granulocytes,NK cells and T cells were
collected,washed,incubatedfor 30 minat 4°C with anti-CD4microbeads,andpassedthrougha
typeMS iron beadseparationcolumnplacedwithin the magneticfield. After extensivewashing
the columnwasremovedfrom the magnetandthe CD4÷adherentcellsflushedfrom the column
with cold buffer. Thesecells were then passedthrough a secondpositiveselectioncolumnto
further purity the DCs. The purity of the sorted populationwas analyzedby labeling the
recoveredcellswith FITC-anti-HLA-DR,anda cocktail of PE-conjugatedmAbsdirectedagainst
CD19, TCRctl3,TCRyS,CD56, and CD14 (to detectany residualNK cells,T cells,B cells, or
monocytes).
Cultureof DC
In some experiments, immunomagnetically sorted DCs were suspended in KPMI 1640
medium (10 s ceils/ml) supplemented with 10% heat-inactivated fetal bovine serum (GibcoBRL,
Grand Island, NY), 10 mM HEPES buffer, 100 _g/ml streptomycin, 100 U/ml penicillin, 50 I.tg/ml
gentamicin, 2 mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 x 10 -5
M 2-mercaptoethanol (2ME), 50 ng/ml human recombinant GM-CSF (R&D Systems,
Minneapolis, MN), and 10 ng/ml highly purified human recombinant TNFo_ from E. coli (Cetus
Corp., Emeryville, CA) [10]. The cells were cultured for 5 days at 37°C in a 5% CO2 humidified
atmosphere.
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Allogeneic mixed lymphocyte response (MLR)
The MLR was performed as described previously [13]. DC stimulator cells were
suspended in RPMI 1640 medium supplemented with 10% heat-inactivated human AB serum (Pel
Freez, Brown Deer, WI), HEPES buffer, antibiotics, nonessential amino acids, sodium pyruvate,
glutamine and 2ME as described above, and irradiated with 3000 cGy delivered from a cesium
source. Serial dilutions of the DC were prepared in triplicate in 96 well round-bottomed plates
(0.1 ml/well) and an equal volume of medium containing 1.5 x 10 _ allogeneic nylon wool
nonadherent T lymphocytes was added to each well (stimulator:responder ratios ranged from
0.01:1 to 1:1). Controls included DC and T cells incubated alone. The plates were cultured for a
total of 5 days, with 1 laCi of 3H-thymidine (3HTdR; NEN-DuPont, Boston, MA) added during
the final 16 hr of culture. Cells were harvested onto glass fiber filters, and the radioactivity
measured by 13-scintillation counting. The results are expressed as counts per minute (cpm).
Digital imaging
Images of cells in cultures were captured as described previously [8] using a VI-470 CCD
video camera system (Optronics Engineering, Goleta, CA) attached to a Nikon DIAPHOT-TMD
inverted microscope (Nikon Inc., Melville, NY) that was equipped with 10x or 20x objectives.
The images were digitized using a QuickCapture frame grabber board (Data Translation Inc.,
Marlboro, MA).
Data analysis
Data were analyzed using a Students t-test analysis.
when p<0.05.
Results were considered significant
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Results
Phenotype of DCs isolated from peripheral blood of normal donors
Freshly isolated peripheral blood DCs are known to be of low buoyant density (<1.077
g,/ml) and lack surface markers expressed by T cells, B cells, NK cells, monocytes/macrophages,
or granulocytes, i.e. they are CD3"CD1 lb'CD14"CD19"CD16"CD20"CD56" [6, 7, 11]. However,
DCs express MHC Class II [7]. Another distinguishing characteristic of freshly isolated
peripheral blood DCs is the expression of CD4 surface molecules [1, 6]. A DC isolation kit
purchased from Miltenyi Biotec Inc. (Sunnyvale, CA) was used for immunomagnetic sorting of
DC from peripheral blood specimens based on the above mentioned characteristics. This isolation
was performed in 2 steps according to the manufacturer's recommendations: PBMC were first
depleted ofT cells, NK cells, and monocytes using a cocktail of mAbs recognizing CD3, CD16,
and CD1 lb, respectively (negative selection step), and then CD4 ÷ leukocytes were obtained by
positive selection [ 1, 2, 5]. Using this technique, we obtained highly-enriched populations of cells
(up to 95% purity) displaying a phenotype consistent with DC as analyzed by flow cytometry, i.e.,
TCRt_I3TCRy_'CD19"CD14"CD56-, but HLA-DR ÷ (Figs. 1A and 1B). When the light-scatter
property of these cells was examined, it was found that their size (as estimated by FSC) was
intermediate to that oflymphocytes and monocytes (Figs. 1C and 1D).
Morphology and function of sorted DCs
Immunomagnetically sorted lin'DR ÷ cells were placed into culture for 5 days with GM-
CSF and TNFtx, and then analyzed by light microscopy. As seen in Fig. 2, these cultures
contained cells with elongated processes typical of more mature DC. Furthermore, these cells
were potent stimulators of a primary allogeneic MLR, as evidenced by their ability to stimulate
'1
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significant proliferation of allogeneic T lymphocytes at stimulator-to-responder ratios as low as
0.01:1 (Fig. 3).
Detection of DC-like cells among peripheral blood mononuclear cells
Based on the information obtained from the sorting experiments, we next determined if
multidimensional flow cytometry could be used to accurately detect linDR ÷ cells directly in
minimally manipulated PBMC preparations (i.e. cells obtained from blood specimens subjected to
Ficoll-Hypaque gradient separation only). PBMC from normal donors were labeled
simultaneously with a PE-cocktail of mAb recognizing the lin-associated markers CD3, CD1 lb,
CD14, CD16, CD19, CD20, and CD56 (first color), and FITC-conjugated anti-HLA-DR (second
color). Cells labeled with isotype control antibodies were included to determine background
fluorescence. Because of the low frequency of lin',DR ÷ cells, we routinely collected 30,000 to
50,000 events to more easily visualize and gate on this population.
As seen in the representative experiment shown in Fig. 4A, a very small subset of linDR*
leukocytes could be detected using this technique. This population represented 0.75 ± 0.04%
(mean ± SE; n=12) of PBMC from normal individuals. Similar levels of lin'DR ÷ cells were
observed using instead a cocktail of FITC-conjugated lineage-associated mAb and TRI-anti-HLA-
DR (Fig. 4B). By gating on the lin'DR ÷ events in quadrant 4 of the bivafiate plot and viewing the
FSC profile, we observed that this subset was intermediate in size to iymphocytes and monocytes,
a characteristic that was similar to the immunomagnetically sorted DC (compare Figs 1D and 4C).
Although these cells were rare, this detection technique was highly reproducible as seen by the
consistency of lin'DR ÷ cells detected in the same sample using the different mAb combinations, as
well by the relatively low variability among replicate samples from five other donors tested (Table
2).
To further characterize this lin-DR ÷ subset and to compare it more closely with
immunomagneticaUy sorted DC, we used 3-color flow cytometry to analyze the co-expression of
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surface molecules that have been associated with DC maturation/activation [6]. PBMC were
labeled simultaneously with a cocktail of FITC lin-associated mAbs, TRI-conjugated anti-HLA-
DR, and PE-conjugated mAb recognizing CD 1a, CD54, CD80, or CD86 surface antigens. A live
gate was set on the lin'DR ÷ cells as shown in Fig. 4B, and these cells analyzed for coexpression of
a third surface marker detected by a PE-conjugated mAb. An example of CD86 coexpression by
lin'DR + cells in a PBMC specimen is shown in Fig. 4D. Using this approach it was observed that
the phenotype of the majority of lin'DR ÷ cells was consistent with that described recently for DCs
freshly obtained from peripheral blood using other isolation techniques, i.e.
CD4+CD54+CD86÷CD80"CD 1a" (Table 3) [6]. Furthermore, this phenotype was similar to that of
the highly-enriched DC obtained by immunomagnetic cell sorting (Table 3).
As further support that the lin'DR ÷ cells detected in PBMC were comparable to sorted
DC, we spiked a sample of PBMC labeled with a PE-lin cocktail alone with purified FITC-DR ÷
DC obtained from the same individual. The sorted DC displayed the same fluorescence and size
characteristics as the DC-like cells gated within the whole PBMC population (data not shown).
Analysis of DC in PBMC of cancer patients
Having determined that the above described 2-color flow cytometric technique could be
used to confidently detect DC-like cells in peripheral blood of normal donors, we applied the same
approach to determine the levels of DC in cancer patients. As seen in Fig. 5, the proportion oflin"
DR + leukocytes in PBMC specimens of breast cancer patients who had undergone prior
chemotherapy was only 0.36+ 0.05% (mean + SE) which was significantly less than that of normal
individuals (p<0.0005). With the exception of patient #3, the majority of lin-DR ÷ eeUs detected in
these patients, like those of normal donors, coexpressed CD4 and CD54 (Table 4). Also with one
exception (patient #2) few or none of the lin'DR ÷ cells detected in PBMC of these patients
coexpressed CD1 a or CD80.
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Even lower levels of lin'DR÷ leukocytes were detected in PBMC samples of cancer
patients recovering from stem cell transplantation (Fig. 5). The frequency of DC-like cells in
these patients who were I-5 months post stem cell transplantation was only 0.14 + 0.06% (mean
+ SE), and was significantly reduced compared to both normal donors and non-transplanted
cancer patients (p<0.0005 and <0.025, respectively). In fact, lin'DR ÷ cells were undetectable in
one transplanted patient.
Discussion
We have evaluated the feasibility of using a simple 2-color flow cytometric technique to
detect DC-like cells in mononuclear cell preparations of peripheral blood of normal donors and
cancer patients. These cells represented approximately 1% or less of the PBMC fraction, a
frequency that is in agreement to that estimated for DC analyzed in a variety of other types of
assay conditions [6, 7, 11 ]. Furthermore, they expressed a phenotype and size that was virtually
identical to that of immunomagnetically sorted DCs, as well as to freshly isolated peripheral blood
DC described in previous reports [2]. However, because our approach allows for detection of
DCs directly in blood samples that have received only minimal manipulation (Ficoll-Hypaque), it
allows for a more rapid, and perhaps more accurate assessment of this important APC population
compared to other DC enrichment procedures. While other investigators have shown that DC-
like cells can be detected in PBMC populations [2], our study is the first to apply
multidimensional flow cytometry to begin to analyze in more depth the frequency and
maturation/activation status of these cells in blood specimens of cancer patients, including those
who are judged as immunodeficient by other criteria (e.g. low numbers of circulating CD4 ÷ T
lymphocytes). Our data suggest that DC testing could become a part of the routine clinical
evaluation of immune competency.
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We haveshownfor the first time that while lin-DR+ leukocytes in PBMC specimens of
breast cancer patients who have received prior chemotherapy phenotypically resemble those
detected in normal PBMC (i.e. CD4+CD86+CD54*CD80"CDla'), this population is reduced by
approximately 50% in the patients. Studies are planned to determine whether this effect is related
to the disease-state or to the chemotherapy. The functional capabilities of the small numbers of
DC-like cells detected in these patients remains to be determined, but it was recently reported that
DC antigen presentation is compromised in cancer patients [3]. In any case, the lower levels of
APCs might contribute to the inability of patients to mount an effective anticancer response.
Similarly, the low levels of lin'I)R ÷ DC-like cells in stem cell transplanted patients could contribute
to the increased susceptibility of these patients to opportunistic infections. Our observations
suggest that the multidimensional flow cytometric technique described here could be used to
monitor DC recovery after transplantation and to evaluate the effect of various treatment
regimens or environmental conditions on DC frequency or maturation. Such a tool might also aid
in identifying therapies that spare or boost immunity.
We found that the 2-color flow analysis of DC could be performed with o_y 2 x 10 6
PBMC, a number of cells that was easily obtained from normal donors, but more importantly, also
from immunocompromised patients who often have low leukocyte counts. Additional cells were
required for the more extensive 3-color analyses. However, as the technology for multicolor
analysis is improving and expanding, it should be possible to simultaneously analyze DC within a
single sample for co-expression of multiple surface and cytoplasmic markers.
Analysis of human DC will also be significantly facilitated if mAb specific for these
populations can be identified. Recently it was shown that some subsets of human peripheral blood
DC express CD83 [11-13]. This surface antigen is not specific for DC, and may not detect less
mature DC subsets [ 13]. However, the availability of antibodies to CD83 has been instrumental in
analyzing cytokine- and chemokine-gene expression in peripheral blood DC, and discrimination of
DC subsets that are susceptible to HIV infection [ 11-13]. Studies to analyze CD83 expression by
the DC detected within PBMC populations are currently in progress.
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Until more direct analysis of DC is possible, the exact composition of the lin-DR ÷
population, and the proportion of cells within this subset that are truly DC-committed cannot be
precisely determined. It is possible, for example, that this population may contain DR + progenitor
cells that are not yet committed to a specific lineage [9]. Whether such cells could be driven
towards the DC lineage, however, is an intriguing question with relevance perhaps for the
treatment of immunodeficient patients. Nevertheless, the co-expression of MHC Class II and
costimulatory molecules by the lin'DR ÷ cells detected using the multidimensional flow cytometric
technique described here indicate that they might possess potent antigen-presenting activity.
Acknowledgments This work was supported in part by subcontract No. NCC 9-36 under the
Texas Medical Center - National Aeronautics and Space Administration/Johnson Space Center
Cooperative Agreement.
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Table 1. Monoclonal antibodies used for cell surface analysis of human dendritic cells
Surface
Antigen Distribution Source"
CD 1a DC; cortical thymocytes Caltag
CD3 T cells Caltag
CD4 DC; T-helper/inducer cells; monocytes/macrophages Caltag
CD1 lb Granulocytes; monocytes/macrophages; NK cells Caltag
CD 14 Monocytes/macrophages; some granulocytes Caltag
CD 16 NK cells; granulocytes; activated monocytes/macrophages B-D, Caltag
CD 19 B cells Caltag
CD20 B cells (except pre-B and plasma cells) Caltag
CD54 (ICAM-1) DC; endothelial cells; many activated cells Caltag
CD56 NK cells; T cell subset B-D;Coulter
HLA-DR DC; some B cells, T cells and monocytes Caltag/B-D
CD80 007.1) DC; activated B cells, T cells and monocytes Calbiochem
CD86 (B7.2) DC; activated B cells and monocytes Calbiochem
"Caltag, Burlingame, CA; Becton-Dickinson 00-D), Immunocytometry Systems, San Jose, CA;
Coulter Corp. Hialeah, FL; Calbiochem, San Diego, CA.
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Table 2 Detection of lin'DR ÷ leukocytes in PBMC of
normal donors
Donor Perce_Lin_R+Cells
No. Testl Te_2 Test3
1 1.0 1.1 1.0
2 0.9 0.9 0.9
3 0.7 0.7 -
4 1.1 0.9
5 0.5 0.5 -
Lin'DR + cells
cytometry.
in PBMC were detected by 2-color flow
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Table 3 3-Color flow cytometric analysis oflin-DR ÷leukocytes in unsorted and
immunomagnetically sorted peripheral blood specimens.
Expt. Percent of lin-DR ÷cells coexpressing the particular antigen
No. CD4 CD54 CD86 CD80 CD 1a
PBMC-1 94.6 98.1 93.2 5.3 6.0
2 87.2 93.6 88.4 0.6 0.3
3 88.2 93.8 93.1 6.0 -
4 92.2 97.4 99.3 1.6 1.3
Sorted 1 98.9 79.4 1.4 -
2 97.6 91.4 2.2 4.9
3 98.8 86.5 3.2 6.7
LinDR + cells in unsorted PBMC or immunomagnetically sorted populations were
analyzed for coexpression of several other surface markers using 3-color flow
cytometric analysis. The sorted cells had been positively selected using an anti-
CD4 mAb and were not reanalyzed for expression of this antigen.
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Table 4 Phenotype of lin'DR + leukocytes of breast
cancer patients
Patient % ofLin'DR ÷ cells coexpressing:
No. CD4 CD54 CD86 CD80 CDla
1 83 92 4 1 3
2 87 99 91 30 n.t.
3 43 7 55 0 0
4 68 51 22 0 0
5 65 55 11 5 0
6 85 97 98 0 n.t
7 54 67 77 0 0
PBMC were analyzed by 3-color flow cytometry as
described in the legend of Fig. 4.
2O
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Fig. 1 Enrichment of lin'DR ÷ leukocytes by immunomagnetic cell sorting. Unsorted PBMC
(Panels A and C) from a normal donor and cells sorted using a DC isolation kit as described in the
Materials and Methods section (Panels B and D) were analyzed by flow cytometry. Markers were
set using PE- and FITC-conjugated isotype control antibodies to exclude >98% of background
events. DC-like cells were characterized as the lin'DR ÷ events in quadrant 4 of the FITC vs PE
dot plots in Panels A and B. The lineage cocktail consisted of PE-conjugated mAbs recognizing
TCRoq3, TCRyS, CD19,CD56 and CD14 antigens. The light-scatter characteristics of the
leukocyte populations are shown in panels C and D. The two major leukocyte populations, i.e.
lymphocytes (L) and monocyte/macrophages (M) are labeled in Panel C. The experiment shown
is a representative experiment from 3 sorts of PBMC from normal donors.
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Fig. 2. Morphology of immunomagnetically sorted lin-DR ÷ leukocytes. Lin-DR ÷ leukocytes from
PBMC of a normal donor were sorted as described in Fig. 1 and cultured for 5 days with
GM-CSF and TNFo_. Note cells with elongated cytoplasmic processes typical of DC (arrow).
22
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Fig. 3 Allostimulatory activity of immunomagnetically sorted lin'DR + cells. Unsorted PBMC and
immunomagnetically sorted linDR ÷ leukocytes were tested for the ability to stimulate allogeneic
lymphocytes in a standard mixed leukocyte reaction. Bars represent mean +SE of replicate
samples. Proliferation of responder cells was evaluated by 3HTdR uptake measured after 5 days
of culture.
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Fig 4 Flow cytometric analysis of lin-DR ÷ leukocytes within PBMC preparations. Panel A:
PBMC of normal donors were labeled with a cocktail of PE-conjugated mAbs recognizing CD3,
CD19, CD20, CD16, CD56, CDllb and CD14, and FITC-conjugated anti-HLA-DR mAbs.
Panel B: The same PBMC population was labeled with a cocktail of FITC-conjugated mAbs
recognizing the lin-associated antigens listed above and TRI-anti-HLA-DR mAbs. Panel C:
Forward light-scatter (size) characteristics of the unseparated PBMC (oo..) and lin'DR ÷ cells
contained within the rectangular gate shown in quadrant 4 of the TRI versus FITC dot plot in
Panel B (_). Panel D: PBMC were labeled simultaneously with FITC-Iin cocktail, TRI-anti-
HLA-DR and PE-anti-CD86, or with the same FITC and TRI labeled antibodies and a PE-
conjugated isotype control antibody. The histograms represent the proportion of lin'DR ÷ cells in
the live gate ofFITC',TRI ÷ events that react with the isotype control ( .... ) or anti-CD86 (_)
mAbs.
24
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Fig. 5 Frequency of lin-DR + cells in PBMC of normal donors and cancer patients. The
percentage of lin'DR ÷ leukocytes was determined by 2-color flow cytometry as described in the
legend of Fig. 4. Patients included 7 breast cancer patients who received prior chemotherapy
(chemo) and 6 patients who had received stem cell transplants (chemo+SC) 1-5 months prior to
testing. Horizontal lines represent the mean.
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ABSTRACT
The characteristics of antigen-presenting cells in carcinomas that involve
the abdominopelvic cavity are unknown. Dendritic cells, a population of
antigen presenting cells have been identified as lineage-negative HI.A-DR*
leukocyte ceils by two-color flow cytometry. We used this criterion to study the
putative dendritic cells in ascltes from 25 patients with peritoneal
carcinomatosis. The mean proportion 4- standard deviation of llneage-negatlve
HLA-DR" cells in ascites were 3. I ± 4.6% (range 0.05 - 17.3%). Most lineage-
negative HLA-DR" ceils expressed CD45RA or CD4 antigens. Dendritic ceils
had low proportions of CD80, CD1 lc, CD45RO and CD58, suggesting that they
were of low maturity. The proportion of lineage-negative HI.A-DR" cells in
ascites was significantly higher compared with the proportion in peripheral
blood from the same patients (4.5 4- 5.7 V 0.5 4- 0.4: P < 0.05). The proportion
of lineage-negative HI.A-DR" ceils that coexpressed CD86 or CD58 was lower in
ascites (56 4- 19 %) than in peripheral blood (91 4- 10°/o, P < 0.05), whereas a
higher proportion of lineage-negative HLA-DR" cells in ascites exp_ CD4.
Relative fluorescence intensity of HI.A-DR was also lower in dendritic cells
from ascites and blood from patients with carcinomatosis than it was in blood
from normal donors. As an indicator of macrophage activation, the
concentration of neopterin in ascitic fluid correlated negatively with the
numbers of lineage-negative HLA-DR" cells in ascites (rs=-0.44, P < 0.05), and
lineage-negative HLA-DR" CD4* ceils (rs=-0.63, P < 0.005), and correlated
positively with the number of lineage-negative HLA-DR ° CD80" cells (rs=0.43, P
< 0.05). The proportion of lineage-negative HI_A-DR" cells also correlated
positively with the concentration of Interleukin-10 in ascitic fluid (rs=0.40, P =
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0.05). These findings suggest that certain factors associated with the tumor
rnlcroenvironment might influence the number of these dendritic ceils and
their expression of function-associated markers.
INTRODUCTION
Ovarian and other M&llerian carcinomas are the most frequent cause of
peritoneal carclnomatosis, although other cancers, including those that
originate in the gastrointestinal tract may spread to involve the serosal and
peritoneal surfaces of the abdominopelvlc cavity. Platinum-based
chemotherapy and, more recently, taxanes have proven useful in the treatment
of tumors of MQUerian origin. Most patients, however, will ultimately die of
cancer-related complications. Tumors that originate in the gastrointestinal
tract are generally less responsive to chemotherapeutic agents.
A number of clinical trials have been conducted on biotherapeutic agents
administered intraperitoneaUy. These studies have utilized recombinant
cytoklnessuch as interferon-a (IFN-a) (Willemse et al., 1990), interferon-7 (IFN-
_) (PuJade-Lauraine et aL, 1996), and interleukin-2 (IL-2) alone (Freedman et
a/., 1997), or with lymphokine activated killer cells (Steis et a/., 1990) or tumor-
infiltrating lymphocytes IT[I.s) (Freedman et a/., 1994). Intraperitoneal
treatments with some of these agents has produced complete responses,
especially in patients who have a minimum of residual disease after prior
chemotherapy. The outcome of intraperitoneal Immunotherapy strategies in
ovarian and other peritoneal carcinomas might possibly be improved when a
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better understanding is acquired of the antigen-presenting cells associated with
these tumors.
Tumor antigen peptides presented within the major
histocompatibility complex (M:HC} class I or II are specifically recognized by the
T-cell receptor {Marrack and Kappler, 1987). The binding of the T-cell receptors
to particular pepUde MHC complexes produces a signal for T-cell activation.
This first signal is transferred to structures within the cell by the monomorphic
CO3 proteins that are in covalent association with the T-cell receptors. In
addition, a need for a second signal has been established (Geppert et o2., 1990).
This signal could be mediated by accessory molecules, such as the intracellular
adhesion molecule-1 and its ligand (CD54) or late -function antlgen-3 (CD58)
(Geppert et aL, 1990; Singer, 1990). A most important, and probably
indispensable signal involves the ligation of CD28 on lymphocytes by
costlmulatory molecules B7.1 (COS0) or B7.2 (CD86) on antigen-presenting
ceils or target cells (june et oL, 1994; Linsley and Ledbetter, 1993). The
expression of both MHC and accessory molecules on tumor cells varies
significantly (Hersey eta/., 1994; V_mky et aL, 1996). Moreover, we have found
that (I) the presence of large numbers of CD3 ÷, CO4 ÷, and CD8 ÷ infiltrating
lymphocytes in solid tumor specimens from ovarian carcinomas in v/vo and (ii)
expansion of TIL-derived T-cell lines in v/tro correlate positively with the
expression of histocompatibility leukocyte class I antigens (HLAs) on these
tumor ceils (Kooi et aL. 1996}.
Melichar et al.
Page 5
CD80 or CD86 are usually absent on tumor cells (V_inky et aL, 1996). In
contrast, professional antigen-presentlng ceils constitutively express MHC
antigens as well as costirnulatory molecules. In fact. MHC class II antigens
and CD28 l/gands are constitutively expressed only on macrophages. B
lymphocytes and dendritic cells (Azuma et al., 1993; Lenschow et al.. 1996;
Young et al., 1992). Dendritic cells are considered to be as effective as, or
perhaps superior, in their ant/gen-presentmg ability compared with either
macrophages or B lymphocytes (BetJes eta/., 1993; Thomas et a/., 1993).
Recently dendritic cells have been shown to influence the direction of an
immune response towards either active immunity or anergy (Ridge et al.. 1996).
Moreover. dendritic ceils in both animals and humans have been shown to be
involved in the control of tumor growth (Celluzzi et aL. 1996; Gabrilovich et aL,
1996a; Gabrilovich et aL, 199613; Hsu et al., 1996; Zitvogel et at.. 1996).
Dendritic ceils were originally defined on the basis of their morphologic
appearance, but the relationship of their precursors to the hemopoletic cell
precursors is not fully defined (Peters eta/., 1996: Steinman, 1991). Because
dendritic cells are present in small numbers and have no specific surface
markers, they are difficult to study tn s/ttL Recently dendritic cells were
characterized by the absence of lineage-specific markers for other leukocytes
and by their expression of HI, A-DR and. in most cases, CD4 antigens (Ferbas et
a/.. 1994; O'Doherty et at. 1994). In the present study we report: (i) the
frequency of lineage negative HLA-DR ÷ leukocytes in the malignant ascites and
peripheral blood of patients with ovarian and other carcinomas that involve
the abdominal cavity. (ii) the expression of costimulation molecules and
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certain other surface markers on these cells consistent wlth that of dendritic
cells, and (111) correlations among the characteristics of dendritic cells in
ascltes according to the levels of cytokines and neopterin in the peritoneal
cavity. These studies show for the first time the characteristics of dendritic
cells associated with ovarian and other abdominal carcinomas. Dendritic cells
may also be important in the therapeutic induction of active immunity.
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MATERIAL AND METHODS
Patients and norma/donors
Specimens of malignant ascttes were obtained during diagnostic and/or
therapeutic paracentesis from 25 patients (Patients 1-25 in Table I). These 25
patients included 20 patients who had epitheUal ovarian cancer and one each
who had granulosa cell ttunor, endometrial cancer, gastric cancer, colon cancer
and adenocarclnoma of unknown origin. Peritoneal washings were obtained
during abdominal surgery from 6 additional patients, including 4 who had
epithelial ovarian cancer, and 2 who had endometrlal cancer (Patients 26-31 in
Table I). Specimens of the peripheral blood were obtained from some of these
patients and from another 3 patients who had gynecologic malignancies
(Patients 32-34 in Table I). The mean age of the patients was 57 ± 12 years
(range 35- 80 years). Peripheral blood specimens were also obtained from 5
normal women donors, aged 35 :k 7 years.
Spectmenpreparatton
Fluid from ascites and peritoneal washings were collected into sterile
bottles and heparin was added. Peripheral blood was collected into heparinized
vacutainer tubes. All samples were processed within 2 hr of collection.
Peritoneal exudate ceils were sedimented from the ascites or washings by
centrifugation at 900 x g for I0 rain. The supematant of ascites was collected
for further analysis and stored at -70°C. The ceils were then resuspended in
calcium/magnesium-free phosphate buffered saline (PBS), layered over a
Histopaque 1077 density cushion (Sigma, St. Louis, MO) and centrifuged for 30
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min at 800 x g. The layer of mononuclear leukocytes was then collected, and
the ceils were counted in a hemacytometer and washed with PBS.
The peripheral blood specimens were diluted with I part of PBS, layered
over Histopaque 1077 and centrifuged at 800 x g for 30 min. Ai_er collection.
the mononuclear leukocytes were counted and then washed with PBS.
cytome 
Phenotyping for the cell-surface antigens was determined by two- and
three-color immunofluorescence using monoclonal antibodies directly
conjugated to fluorescein isothiocyanate (FITC), R-phycoerythrln (PE), or Tri-
color. Antibodies were obtained from Caltag (Burlingame, CA), Becton-
Dickinson (San Jose, CA), Calbiochem (La JoUa. CA), Olympus (Lake Success,
N-Y) and Biosource International (Camarillo, CA). The specificity and source of
these monoclonal antibodies are listed in Table II.
For two-color flow cytometric detection of lineage-negative HIA-DR" cells
in preparations of mononuclear leukocytes, I08 cells were incubated for 30 rain
at 4"C with FITC-conJugated anti-I-H2k-DR, with a coc.ktafl of PE-conJugated
monoclonal antibodies directed against the following leukocyte antigens: CO3,
CD11b. CD14. CD16, CD19. CO20. CD54, CD56 and CD58. The latter lineage
cocktail was tit.rated to label all natural killer cells, T- cells, B- cells,
monocyte/macrophages and granulocytes simultaneously. Cells labeled with
PE- and FITC-conJugated isotype control monoclonal antibodies that were
nonreactive to human cells served as controls. The labeled cells were washed
with PBS. fixed in I% paraformaldeV :el analyzed using a FACScan flow
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cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA)
equipped with a single 488-nm argon laser and 3 fluorescence detectors with
filter settings for FITC (530 nm), PE (585 run) and Tri-color (> 650 nm). A total
of 20,000 to 50,000 events were collected in list mode and analyzed using
FACScan Reseazch Soilware (Becton Dickinson).
For three-color flow cytometric analysis, 10 8 cells were labeled
simultaneously with a cocktail of FITC-conJugated llneage-speclfic antibodies,
Tri-color-conJugated anti-HLA-DR, and PE-conJugated monoclonal antibodies
that recognize other surface determinants. The cells were washed with PBS
and fixed with 1% paraformaldehyde. For flow cytometric analysis, a live gate
was set on the lineage-negative HLA-DR* cell population, and these cells were
then analyzed for coexpression of a third marker identified as positive events
(above background of isotype control) within the PE- channel. For some
antigens, the expression was evaluated by relative fluorescence intensity as the
fluorescence intensity of the antigen divided by the flourescence intensity of
the isotype control. Figure 1 is a representative plot that shows the detection
of a lineage-negative I-II_-DR _ cell population. Histograms in Figure 2 show
representative results for surface costimulatory and adhesion molecules and
activation markers.
Enzyme-/tnked/mmunoabsorbant assay
Specimens of ascites were centrifuged at 900 x g. Supematants were
stored at -80°C until testing could be done. Concentrations of interleukin-4
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(IL-4). Interleukin-10 (IL-10), tumor necrosis factor-a {TNF-a). granulocyte-
macrophage colony-stlmulatlng factor (GM-CSF) and IFN-7 were determined in
the ascitlc fluid using commercially available enzyme-linked immunoabsorbant
assay (ELISA) kits (BioSource International). The ELISA kit for neopterin was
supplied by IBL (Hamburg, Germany). Testing was performed according to the
manufacturer's instructions. The following standards were used as the lower
limits of detectabtllty:, for IL-4 and TNF-_x, 2 pg/ml, for Ile10, 6 pg/ml, for GM-
CSF 8 pg/ml, for IFN-7 4 pg/ml, and 1.35 nmol/1 for neopterlns.
smusta_z/ana_sts
Statistical significance of differences between unpaired observations was
studied using the Mann-Whitney U test. The Wflcoxon paired test using
StatView software (Abacus Concepts, Berkeley, CA was used for paired
observations.). Correlations were studied by the Spearman rank coefficient, and
correction for ties was performed with StatView software. Significance was
determined as P < 0.05.
Re.ultra
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Lineage-negat/oe H/A-DR" ce//s in ma//gnant asc/tes and pertphera/ b/ood of
_Uients wtth mal_nanc_s of the abdo_pelv_c cavity
The" proportion of lineage-negative HLA-DR" mononuclear leukocytes in
malignant ascites are shown in Table III. The mean proportion of these cells ±
standard deviation was 3.1 4- 4.6% and ranged from 0.05 to 17.3%. The mean
number of llneage-negatlve I-ILA-DR* cells was 8.0 4- 9.5 x 10 e cells/L, (range
0.1-31.6 x 108 cells/L. A trend that favored higher numbers of lineage-negative
HLA-DR* ceils was observed in the malignant ascltes from patients without a
history of prior chemotherapy compared with the number seen in malignant
ascites from previously treated patients 11.3 4- 10.2 x 106 cells/L, (range 1.1-
27.0 x I0 e ceils/L)V 6.2 ± 9.2 x I06 cells/L, (range 0.1-31.6 x 108 cells/L), but
thls difference was not statistically significant. There was also no significant
difference in the proportion of lineage-negative HLA-DR ÷ cells in untreated and
treated patients (3.0 ± 2.8%, (range 0.3-7.7%) V 3.1 ± 5.2%, (range 0.05-17.3%),
respectively). In contrast to the findings in malignant ascites, lineage-negatlve
I-ILA-DR* cells were present in smaller proportions in peritoneal washings of 6
patients who had various abdominal cancers (0.15 + 0.1 V 3.1 + 4.6: P <
0.005).
Paired specimens of ascltes and peripheral blood were obtained from 7
patients. The proportions of lineage-negatlve HLA-DR" cells was significantly
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higher in the malignant ascltes than m the peripheral blood (4.5 + 5.7% V 0.5
± 0.4%: P < 0.05) (Fig. 3A).
Peripheral blood specimens of 17 patients who had abdominal cancer
(ascites in 8 patients and tumor without ascltes In 9 patients) contained 0.4 ±
0.3% of IIneage-negatlve HLA-DR" cells (Table IV). The proportion of lineage-
negative HLA-DR" cells in peripheral blood specimens from patients with
peritoneal or ovarlan malt_-ncles was slgnfficantly lower than the proportion
In peripheral blood specimens from normal donors (0.4+0.3% V 0.9+0.396, P <
0.02).
Cell surface differentWtion and acthaa_n markers on lineage-negatlve HIA-DIT
eells in ascltes and peripheral blood of _ with carcinomas of the
abdominopelvfi: cavity
Three-color flow cytometric analysis of lineage-negative HLA-DR" cells in
ascites revealed the following cell proportions: CD4": 92 ± 9% (range 63-100%)
and CD45RA÷: 94 ± 12% (range 54-100%) (Tables [] and IV, Fig. 3B). The
proportions of lineage-negative HLA-DR" cells that coexpressed CD4 antigen
was significantly higher in malignant ascites compared with peripheral blood
specimens obtained from the same patients (95 ± 4% V 63 ± 17%: P < 0.05.
(Fig. 3B}.
The proportions of lineage-negative HI.A-DR" cells in malignant ascites
that expressed the costimulatory molecules CD80 and CD86 varied among
specimens from individual patients {Table Ill). The mean proportion of lineage-
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negative HLA-DR" cells from ascites that coexpressed CD80 was 5 ± 14% (range
0-63%] (Table III), whereas the mean proportion in peripheral blood was 4 ± 8%
(range 0-12%) (Table IV). In I specimen of malignant ascites from 1 patient,
CD80 ÷ llneage-negatlve HLA-DR" cells were detected at a very high frequency,
63%. The mean proportion of lineage-negative I-ILA-DR" cells in ascites that
coexpressed CD86 was 47 + 30% (range 0-8896). The mean proportion of
llneage-negatlve HLA-DR" ceils in the peripheral blood that coexpressed CD86
was 82 ± 25% (range 4-10(O) When the proportions of CD86 ÷ llneage-negatlve
HLA-DR ÷ cells were compared In paired samples of ascites and peripheral blood
from the same patients, the frequency of CD86 + cells was significantly lower in
lineage-negative H/A-DR" ceils from ascites than peripheral blood (56 ± 19% V
91 ± 10%: P < 0.05) (Fig. 3c).
The mean proportion of ascitic lineage-negative HLA-DR" cells that also
expressed CD54 was 98 ± 2% (range 93-100%) (Table HI). In contrast,
coexpression of CD58 in peripheral blood specimens ranged from 1 to 48%
(mean 13 _ 14%), and the proportion of CD58 ° ceils was significantly lower on
llneage-negative HLA-DR" cells from ascites than those from peripheral blood in
6 paired specimens (I 1 ± 18% V68 ± 22%: P < 0.05 (Fig. 3d).
CD11c, which is a marker of maturation, was infrequently detected on
llneage-negative HLA-DR" cells from ascitic fluid (mean 4 ± 8%, range 0-34%)
(Table Ill). The proportion of lineage-negative HLA-DR" cells that also
expressed the CD45RO antigen correlated positively with lineage-negative HLA-
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DR" cells that expressed either CDI lc (rs = 0.763: P < 0.02, Fig. 4a), or CD80
(rs= 0.598, p< 0.05, Fig. 4b). The mean proportions of lineage-negatlve HIA-
DR* cells in ascites that were CD45RO ÷ appeared to be lower compared with
that in peripheral blood (7 + 12% V 19 ± 18%), whereas the proportion of
lineage-negatlve HLA-DR ° cells that were CD45RA ° appeared to be lower in
peripheral blood than in ascites (70 ± 13% V 94 ± 12%). but these results were
not statistically significant.
Because cells of the monocyte/macrophage lineage may represent a
population of antigen presenting ceils in the peritoneal cavity that is different
at the functional level from a population of dendritic ceils, we compared
certain maturation/activation-associated markers on CD14" macrophages and
lineage-negative HLA-DR" ceils. Figure 5 is an example from an analysis of one
specimen which shows macrophages from peritoneal fluid expressing higher
proportions of CD86, CD58 and CDI lc compared with the expressions seen on
lineage-negative HLA-DR" cells: CDI4" cells were mostly CD45RO'.
As shown in Figure 6, the relative fluorescence intensity of I-ILA-DR on
lineage-negative HLA-DR" cells Was significantly lower in peripheral blood (21.8
+ 13.6: P < 0.05) and ascites (15.0 ± 8.1: P < 0.01) of patients compared with
those seen in peripheral blood from normal donors (51.2 + 25.1).
Lineage-negative HLA-DIT cells and production of cytokines and neopterin in ascitic
jaa
Melichar et al.
Page 15
Because the number and function of dendritic cells may be influenced by
the cytoklne microenvironment (Buelens et al., 1995; Everson et al., 1996,
Mitra et al., 1995), we set out to determine whether the numbers of dendritic
cells correlated with (i) the ascitic fluid concentrations of certain cytokines
involved with T-ceU activation and (il) with neopterin concentration as an
indicator of macrophage activation. Detection of cytokines and neopterin was
performed by ELISA as described in the Materials and Methods. IL-4 was not
detected in specimens from 8 patients, and GM-CSF was detected in only 2 of 9
ascltes. IFN-7 and TNF-a were not detected in any of the specimens from 25
patients. In contrast, IL-10 was detected in most of the specimens examined.
The mean concentration of IL-10 was 71.4 + 82.5 pg/ml (range 0-287 pg/ml)
and the concentration of IL-10 detected correlated positively with the
proportions of lineage-negative I-ILA-DR" cells detected in ascites (rs = 0.40: P =
0.05, Fig. 7a}. Neopterln was detected in all but 1 of the ascites (mean 19.1 ±
17.5, range 0-76 nmol/l). The concentrations of neopterin correlated negatively
with the numbers of llneage-negative I-II_-DR" cells (rs =-0.44: P < 0.05, Fig.
7b), but correlated positively with the percentages of lineage-negative HI_-DR*
cells that coexpressed CO4 (rs = - 0.63: P < 0.005, Fig. 7c), or CO80 (rs = 0.43,
P < 0.05, Fig. 7d).
Discussion
Dendritic cells are antigen presenting cells that appear to have an
important role in the activation of specific immune responses /n v/vo (Ridge et
a/.. 1996; Steinman. 1991). Because specific markers for human dendritic cells
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have not been identified we utilized an alternative method that is based on
defining the dendritic ceU population by determining the absence of leukocyte-
lineage markers and positlvity for HLA-DR (Ferbas et al., 1994; O'Doherty et al.,
1993). The use of two-color flow cytometry in the present study enabled
quantitation of dendritic cells through the detection of lineage-negative HIA-
DR* cells. Malignant ascites will usually provide large numbers of cells that
can be recovered without extensive manipulations, e.g., enzymatic treatments
that might cause significant alterations in a minor cell population such as
dendritic cells (Abuzakouk eta/., 1996). Our study included patients who had
received prior chemotherapy and who had not. We attempted to determine
whether the variations in the numbers of lineage-negative HI.A-DR" cells in
ascites were related to prior chemotherapy. Significant differences could not be
detected in either the percentages or number of lineage-negative HI.A-DR" cells
from previously treated or untreated patients. A larger sample size may be
required to demonstrate differences between these two patient subgroups.
Dendritic cells may be detected at most anatomic sites (Steinman, 1991).
Using different methods of detection from that used here, 2% (Kubicka eta/.,
1985) to 6% (BetJes eta/., 1993) of peritoneal dendritic cells were detected in
the peritoneal cavity of patients without a diagnosis of malignant disease.
Dendritic cells have also been observed in solid tumor sections of certain
nongynecologic tumors by immunohistochemical analysis, and a dense
dendritic cell infiltrate has sometimes been seen (Furihata et at, 1992; Inoue et
a/., 1993). These studies did not include an analysis or" differentiation anUgens
or anUgens associated with activation.
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In agreement with previous reports, llneage-negatlve HLA-DR" cells were
found to constitute a minor population in peripheral blood (O'Doherty et al..
1994). The proportions of llneage-negative HLA-DR ° cells was substantially
lower in the peripheral blood of patients with abdominal or pelvic cm'cinomas
compared with the proportion seen in normal donors. This difference could
possibly be related either to prior systemic treatments that patients had
received or to the disease process itself.
The number and proportion of dendritic cells that express antigens of
differentiation and activation could be affected by the presence of cytokines in
the microenvironment. IL-10 is a cytol0ne that is frequently detected in the
ascltes of patients with peritoneal carcinomatosis. We compared the
production of IL-10 with the proportions of dendritic ceils, and found that the
proportions of llneage-negative HLA-DR* cells correlated positively with the
concentration of IL-10 in the ascitic fluid. This could be a direct effect of IL-
l0. IL-10 may be produced by dendritic celia or other IL-10-producing
leukocytes in the peritoneal cavity such as macrophages, which are present in
large numbers in patients who have ovarian or peritoneal carcinomatosls.
Because neopterin is a product of activated macrophages we measured the
concentrations of neopterin in ascites to determine whether there was an
association with the number or proportions of dendritic cells. Neopterin was
detected in most of the ascites, but its concentration in ascites correlated
negatively with the numbers of lineage-negative HLA-DR ° cells. These results
could be related to a previous association that has been shown between
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neopterin production and depressed immunologic responses (Melichar et al..
1996}. Moreover. others have found an association between neopterin levels
and poor prognosis in patients with certain cancers (Reibnegger et al.. 1986;
Weiss et aL. 1993).
The antigen-presenting function of dendritic cells depends on the
coexpression of MHC class II antigens and costtmulatory molecules (June et
a/., 1994; Lenschow eta/., 1996; Ltnsley and Ledbetter, 1993). The intensity of
I-KA-DR expression was detected at significantly lower levels on dendritic cells
of peripheral blood and ascites from patients compared with levels found on
peripheral blood cells from normal donors. Expression of CD80 on lineage-
negative HLA-DR" ceils was low or absent in most of the specimens studied. In
contrast, CD86 was usually present but at significantly lower levels on lineage-
negative HLA-DR* ceils from ascites compared with the levels found on
peripheral blood. This finding suggests that certain as yet undefined factors in
the tumor microenvironment could have down-regulatory effects on CD86
expression on lineage-negative HLA-DR* cells, or could otherwise influence the
maturity of dendritic cells in the peritoneal cavity. IL-10 has been shown to
decrease the expression of CD86 antigen on human dendritic ceils (Buelens et
a/., 1995). In the current study, IL-10 was detected in most ascites but no
relationship was detected between the expression of CD86 on lineage-negative
HI.A-DR" cells and the concentration of IL-10 in ascitic fluid. However. this
does not necessarily imply that IL-10 is not an important contributing factor to
the reduced proportion of dendritic cells that express either CD80 or CD56 in
V/DO.
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The finding of a low expression of MHC class II antigens and
costtmulatory molecules on lineage-negative HLAoDR* cells in ascites from
patients with peritoneal carctnomatosis suggests that dendritic cells may not
function adequately as antigen-presenting cells in the tumor microenvtronment
of these patients, and this aspect deserves further study. Low expression of
MI-IC class II antigens could be responsible for suboptimal stimulation through
the T=cell receptor, which then increases the oppommlty for an anerglc
response (Krtmmlel and Allison. 1995; Lenschow eta/.. 1996; IAnsley and
Ledbetter, 1993). Decreased expression of costlmulatory factors on the lineage-
negative HLA-DR" ceils could have a similar result.
In a study of accessory molecules on lineage-negative HLA-DR" ceils, we
observed high expression of CD54. CD58 expression, however, was variable
and significantly lower in ascites th_Ln in peripheral blood. CD45RO and
CD11c have been reported to identify a subset of dendritic ceils that have
undergone activation and differentiation (O'Doherty et a/., 1994). Our studies
show that the proportion of dendritic ceils in ascites that express these
markers is lower than the proportion of dendritic cells in peripheral blood.
Dendritic cells have been reported to show a decrease in CD4' expression during
the differentiation process (O'Doherty et at., 1993). The lower proportion of
CD4" lineage-negative HI.A-DR" ceils in the peripheral blood compared with
that in ascites may be an indication of less mature functional characteristics
of lineage-negative HI.A-DR" leukocytes in malignant ascites. The same
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conclusion could be reached from the express/on of the CD45 tsoform on
ILneage-negat./ve HLA-DR ° cells/n per/pheral blood and ascltes.
In summary, we have detected I/neage-negat/ve I-II_-DR ÷ leukocytes /n
the mal/gnant asc/tes assoc/ated w/th peritoneal carclnomatos/s. These cells
show a pattern of marface ant/gens that are character/st[c of less mature
dendritic cells. Decreases /n the express/on of MHC class II ant/gens and
cost/mulatory or accessov/ molecules on dendr/t/c cells associated wlth
peritoneal carc/noma could be of importance/n enabl/ng the tumor to evade
recognition by the host tmmune system.
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FIGURE 1-- Flow cytometric analysis of lineage-negative HLA DR + ceils
Specimens were processed as described in Material and Methods and
stained with a cocktail of PE-conJugated (a and b), or HTC-conJugated (c and
d) monoclonal antibodies against leukocyte lineage antigens, and FIT_-
conjugated (b), or Tri-color-conJugated (d) antibody against I-KA-DR, or the
appropriate Isotype control antibody (a and c). Cells were then analyzed by
flow cytometry, and the numbers of cells negat/ve for leukocyte lineage antigens
and positive for I-ILA-DR were determined. The figure shows results of a
specimens from a representative (Patient 21). Lineage-negative HLA-DR ÷ ceils
represented 5.1% of all mononuclear cells in this specimen. A live gate was
placed on the llneage-negative H/A-DR* cell population (e), to analyze the
expression of other surface antigens (see Flg. 2).
FIGURE 2-Expression of differentiation and activation markers on lineage-
negative HI.A-DR + cells
An ascities specimen from Patient 21 was processed and stained as in
Figure 1. In addition to the cocktail of FITC-conJugated antibodies against
leukocyte lineage markers and Tri-color-conJugated anti-H/A-DR, the ceils
were labeled with a panel of PE-conJugated antibodies with reactivity to
antigens directed to differentiation and activation associated antigens. A llve
gate was placed on the lineage-negative HI.A-DR" cell population (Fig. l e), and
5000 events were collected. The figure shows the following histograms: (A) IgG 1
Isotype control antibody, (b) CD86, (c) CDS0, (d} CDIIc; (e) IgG2 Isotype
control. (f) CD54. (g) CD58, (h) CD4, (i) CD45RA and (J) CD45RO.
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FIGURE 3- Comparison in peripheral blood and malignant ascites of the
proportions of llneage-negattve HLA-DR ° cells and the coexpression of CD4,
CD86 and CD58 surface markers on these cells
Specimens of ascltes (solid bars) and peripheral blood (hatched bars)
obtained from the same patients were processed as described in Materials and
Methods and analyzed (a) for proportions of llneage-negatlve HI,A-DR* cells,
expression of (b) CD4, (c) CD86 and (d) CD58. Values are shown for 7 patients
except for (d) which shows values for 6 patients. Differences between findings
in peripheral blood and ascites were statlstically significant (Wflcoxon paired
test, p < 0.05}.
I_IGURE 4-- Correlation between the number of llneage-negatlve I-II.A'DR +
cells, IL-I0 concentrations, and the phenotyplc markers
The percentage of CD45RO* llneage-negative HI.A-DR ° cells in ascites
was positively correlated with the proportion of ceils that were (a) CDI Ic °, and
Co) CD80 °. Spearman correlation coefficients (rs) and significance levels are
indicated on the figure.
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FIGUI_ 5-- Comparison of cell surface markers on lineage-negative HI.A-DR"
ceils and CD 14" ceUs in malignant ascites
Cells from Patient I I were stained as described in Figures 1 and 2 using
FITC-conJugated anti-CD14 and a panel of PE-conJugated antibodies with
speciflcitles for activation and differentiation antigens. Proportions of lineage-
negative I-KA-DR" or CD14" cells coexpressmg each antigen indicated on the
vertical axis. LN_DR ". Lineage-negative HLA-DR _ cells.
PIGUR_ 6- Relative expression of HI.A-DR on LN-CD4 + ceils
Ceils from perlpheral blood of normal donors and patients and malignant
ascites were stained with FITC-conJugated leukocyte lineage cocktail, PE-
conjugated anti-CD4, and Tri-color-conJugated anti-HI.A-DR or Tri-color
isotype control. A live gate was placed on the lineage-negatlve CD4" population
(not shown). Relative fluorescence intensity of H/A-DR expression was
determined by dividing the mean fluorescence intensity of I-II_-DR stained ceils
by the mean fluorescence intensity of the isotype control as described in
Materials and Methods. The relative fluorescence Intensity of I-ILA-DR in the
lineage-negative I-ILA-DR ÷ CD4 ÷ cell population was significantly higher in
normal donors than in peripheral blood (Mann-Whitney U test, P < 0.05) or
ascites (P < 0.01) from patients.
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FIGb'RB 7- Proportions of llneage-negatlve HLA-DR" cells that express surface
antigens associated with differentiation and activation correlated with the
concentrations of IL-I0 and neopterin in ascitic fluids.
The proportion of llneage-negatlve HLA-DR ° cells and those coexpresslng
CD4 or CD80 in ascttes were determined by two- and three- color flow
cytometry as described for Figures 1 and 2. Concentration levels of IL-10 and
neopterln in ascltlc fluid were meamrred by EUSA.
(a) The concentrations of IL-10 correlated positively with the percentage
of lineage-negative HI.A-DR* cells, (b) Concentrations of neopterin correlated
negatively with the number of lineage-negative I-II_-DR ÷ cells and (c) with the
expression of CD4 on these ceils (d) Positive correlation was observed between
the concentration of neopterin and the expression of CD80 on llneage-negative
HLA-DR ° ceils.
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CUn/cal and pathological characte_dstlcs of patients
Age (y_| Disease Tumor h/stology Grade
eta_e
66' Recurrent PD
2 63 Recurrent NA
3 41 l]Ic PD
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undifferentiated ovarian ¢mrcinoma
Adenocarclnoma of unknown ori_n
Serous ovarian carcinoma
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spindle cell sarcoma
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12 58 _t Serous ovmlm1_ PD
13 50 Recurrent Serous ovarian carc/noma PD
14 70 I]Ic Mixed Mallerian tumor PD
15 62 Recurrent UndifferenUated ovarian carcinoma PD
16 37 Recurrent Clear cell ovarian carcinoma NS
17 35 _Ic Undifferentlatedovarian carcinoma PD
18 48 rnc Serous ovarian carcinoma PD
19 59 Recurrent Colon adenocarclnoma WE)
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21 40 Recurrent Serous ovarian carcinoma PD
22 45 Ic Granulosa cell tumor WE)
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Mixed-- serous.
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breast carcinoma
27 67 Recurrent Serous ovarian carcinoma PD
28 71 Rectm-ent Serous ovarian carcinoma PD
29 58 Recurrent Serous _ carcinoma PD
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32 47 I Serous ovarian carcinoma PD
33 65 Recurrent Serous ovarian carcinoma PD
34 52 Recurrent Mixed. undifferentiated ovarian carcinoma PD
35 46 Recurrent Granulosa cell tumor WD
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APPENDIX 3 C.A. Savary, Ph.D.
flMSA
A Pioneering
Educational Community
December 4, 1996
Dr. Cherylyn Savary
Dept. of Surgical Oncology
MD Anderson Cancer Center
151 Holcolm Bvld., PO Box 18
Houston, TX 77030
Dear Dr. Savary,
One of the goals of IMSA's Mentorship Program is to develop young scientists and
scholars who not only understand and experience research, but are able to make a
significant contribution to the evolving body of knowledge. This is an ideal, and although
most never reach his level as high school students, a few do. Those few have
extraordinary mentors who are able to guide the students' development of specific
research skills and concepts, immerse them in realities of the process and at the same
time instill excitement for research, structure the experience to stretch and
accommodate the student's talents, and be an advocate and friend in the often tangled and
uncertain process.
You are one of these rare mentors; please know how much this is appreciated.
Manu Goyal is one of eleven Illinois students selected to represent the state at this year's
AJAS/AAAS (American Junior Academy of Science/American Association for the
Advancement of Science) annual conference in Seattle in February. Manu will present
his paper, Consequences of Heat-Shocked Proteins and the Dendritic Cell-Tumor
Interaction in the Immune Response Against Breast Cancer, which was done under your
guidance. I hope you will be able to attend AAAS and hear the presentation. Students will
give both oral and poster presentations Friday, February 14; poster presentations from
10 AM -12:30 in Hall C4 of the Seattle Convention Center, oral from 2-5:15 PM (in
six concurrent sessions) in rooms 615-620 of the center. Students will also have the
opportunity to visit with scientists, tour research facilities, and attend AAAS conference
sessions. This is such an incredible opportunity, and could not have happened without
your generous and exceptional guidance.
Again, thank you so much for everything you have done for Manu. Hope to see you
in Seattle.
Enclosed are the students' abstracts: I thought you might find them interestingl
Sincerely,
Dr. Peggy Connolly
Mentorship Coordinator
cc: Dr. Raphael Pollock
1500 West Sullivan Road
Aurora, IL 60506-1000
708-907-5000 Tel
708-907-5976 Fax
aPL_u_x
3 C.A. Savary,
American Association for the Advancement of Science
1997 AAAS Annual Meeting and Science Innovation Exposition - AMSIE '97
American Junior Academy of Science
Poster Abstract Form- Deadline: November 1, 1996
Category (Circle One): Education Life Physical Social
Ph.D.
Consequences of Heat-Shocked Proteins and the Dendritic Ceil-Tumor Interaction in
the Immune Response Against Breast Cancer. MANU S. GOYAL (Illinois
Mathematics and Science Academy, 1500 West Sullivan Rd., Aurora. IL 60506-1000),
DR. CHERYLYN A. SAVARY (Dept. of Surgical Oncology, MD Anderson Cancer
Center, 1515 Holcolm Blvd., PO Box 18, Houston, TX 77030)
Dendritic Ceils (DC) are professional antigen-presenting cells that have been shown to
effectively immunize lymphocytes against tumors. This study investigated DC ability
to kill, bind, and respond to breast tumor cells. Some of the tumor cells were heat-
shocked prior to incubation in order to induce Heat-Shocked Proteins (Hsp) and
investigate their ¢ffea on DC. Hsp have been attributed as targets to the immune
system as well as protective aids to breast lxtmor cells. No significant tumor _,tasis by
DC was detected as tested in a _tCr release assay. We found isolated DC to bind to
tumor cells as measured using flow cytomet_ analysis, but when B-cells and T-cells
were included, they seemingly did not. This suggests that B-Cell, T-Cell, and DC
ratios may affect the immune response to breast cancer. Hsp made no significant
diffenmce in this test. The expression of several DC surface markers, measmcd by flow
cytometry analysis, increased when incubated with breast tumor ceils. Hsp lowered this
expression significantly. This suggests that Hsp may protect breast tumors fi'om the
immune system. These results indicate a novel rule for both Hsp and DC, and may
potentially lead to a new form of immunotherapy for breast cancer.
Presenter's Name: Manu S. Goyal
Mailing Address: 228 Whispering Hills Rd.
City/State/Zip: Naperville, IL 60540
_hone: (630) 420-8880 (weekends)
: (630) 907-5250 (weekdays)
School Presenter Attends: Illinois Mathematics
and Science Academy (IMSA)
Cummt Grade Level: 12th
Academy You Represent: Illinois
Junior Academy of Science
Funding Sponsor: IMSA Fund for
Advancement of Education
Research Advisor: Dr. Cherylyn A. Sava_
Affiliation: MD Anderson Cancer Center
Daytime Phone: (713)792-3134
Name of School Sponsoring Research:
MD Anderson Cancer Center/NASA Shazp
Academy Sponsor: Dr. Peggy Connolly
Daytime Phone: 630-907-5985
